Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence and Safety of 13vPnC Booster in Children
NCT01026038Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2010
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Prevnar 13 in pneumococcal infection, sponsored by Pfizer. Primary endpoints: Serotype-specific Pneumococcal IgG Geometric Mean Concentration, Percentage of Participants With Prespecified Local Reactions and 1 more. Started Apr 2010; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01026038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026038.